Pembrolizumab as first-line therapy in poor performance status patients with advanced non-small-cell lung cancer highly expressing PD-L1: an open-label, single arm, multicenter, phase II study
Phase 2
- Conditions
- advanced non-small cell lung cancer
- Registration Number
- JPRN-UMIN000030955
- Lead Sponsor
- Department of allergy and respiratory medicine Okayama University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
Not provided
Exclusion Criteria
1) comordity of auto-immune disease 2) history of organ transplantation 3) symptomatic brain metastasis (patients with stable condition for more than 7days after radiation will be allowed.) 4) carcinomatous meningitis 5) presence of other cancer within 2 years of registration 6) presence of severe comordity
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method objective response rate
- Secondary Outcome Measures
Name Time Method progression free survival overall survival safety quality of life explore possible biomarkers